{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-21-000017","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.951652+00:00","generated_at":"2026-06-28T10:40:35.644683+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sera Prognostics Q3 net loss widens to $9.9M; cash $82.5M; salesforce scaling to 26 reps","bullets":["Revenue $23K vs $5K YoY; net loss $9.9M vs $5.1M YoY.","Operating expenses $9.5M (R&D $2.7M, SG&A $6.7M) up from $4.6M due to scaling commercial ops and public company costs.","Cash & equivalents $82.5M plus $67.5M available-for-sale securities.","Salesforce now 26 reps; appointed Paul Kearney as Chief Data Officer, Zhenya Lindgardt to Board, Woodrow Myers as advisor.","Published health economic study showing PreTRM test could reduce $54M in costs; clinical validation study published."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-21-000017","json":"https://secwatch.observer/filing/0001534969-21-000017.json","markdown":"https://secwatch.observer/filing/0001534969-21-000017.md","text":"https://secwatch.observer/filing/0001534969-21-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496921000017/0001534969-21-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496921000017/sera-20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:40:35.644683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}